We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
-14.02%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$123M
AUM Growth
-$33M
Cap. Flow
-$6.88M
Cap. Flow %
-5.57%
Top 10 Hldgs %
81.99%
Holding
44
New
1
Increased
4
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$2.24M
2
GERN icon
Geron
GERN
+$992K
3
LONA
LeonaBio Inc
LONA
+$431K
4
KALV
KalVista Pharmaceuticals
KALV
+$305K
5
CABA icon
Cabaletta Bio
CABA
+$82.4K

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$4.41M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$4.38M
3
OCS icon
Oculis Holding
OCS
+$557K
4
GTLB icon
GitLab
GTLB
+$353K
5
MRUS
Merus
MRUS
+$339K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$38.2M 30.9%
225,688
– –
ILMN icon
2
Illumina
ILMN
$30.2B
$16.4M 13.25%
122,533
– –
HRMY icon
3
Harmony Biosciences
HRMY
$2.02B
$12.1M 9.78%
368,665
– –
SGEN
4
DELISTED
Seagen Inc. Common Stock
SGEN
$9.99M 8.09%
47,096
– –
OCS icon
5
Oculis Holding
OCS
$672M
$6.67M 5.4%
606,684
-44,416
-7% -$557K
SLGC
6
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$4.05M 3.28%
1,696,558
– –
EXAI
7
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$3.89M 3.15%
859,892
– –
XENE icon
8
Xenon Pharmaceuticals
XENE
$6.06B
$3.64M 2.95%
106,680
-7,700
-7% -$288K
MRUS
9
DELISTED
Merus
MRUS
$3.23M 2.62%
137,038
-13,962
-9% -$339K
REPL icon
10
Replimune Group
REPL
$880M
$3.16M 2.56%
184,739
– –
KALV
11
DELISTED
KalVista Pharmaceuticals
KALV
$2.26M 1.83%
234,573
+29,853
+15% +$305K
ONC
12
BeOne Medicines Ltd
ONC
$32.5B
$2.16M 1.75%
12,022
– –
ALPN
13
DELISTED
Alpine Immune Sciences Inc
ALPN
$2.09M 1.69%
+182,280
New +$2.24M
INCY icon
14
Incyte
INCY
$24.2B
$1.85M 1.5%
32,022
– –
GERN icon
15
Geron
GERN
$815M
$1.6M 1.29%
753,550
+365,550
+94% +$992K
EXEL icon
16
Exelixis
EXEL
$13.4B
$1.4M 1.14%
64,200
– –
BOLT icon
17
Bolt Biotherapeutics
BOLT
$7.65M
$1.21M 0.98%
58,348
– –
PACB icon
18
Pacific Biosciences
PACB
$441M
$1.14M 0.92%
136,655
– –
RANI icon
19
Rani Therapeutics
RANI
$89.9M
$1.07M 0.87%
493,584
– –
RYTM icon
20
Rhythm Pharmaceuticals
RYTM
$6.81B
$919K 0.74%
40,070
– –
TRDA icon
21
Entrada Therapeutics
TRDA
$262M
$775K 0.63%
49,082
– –
CABA icon
22
Cabaletta Bio
CABA
$427M
$718K 0.58%
47,150
+6,027
+15% +$82.4K
ARGX icon
23
argenx
ARGX
$53.5B
$703K 0.57%
1,430
– –
JBIO
24
Jade Biosciences
JBIO
$1.19B
$650K 0.53%
1,370
– –
ACAD icon
25
Acadia Pharmaceuticals
ACAD
$4.36B
$625K 0.51%
29,984
– –
1
2

Similar funds

TCM
TT Capital Management Coto De Caza, California $121M AUM 1.94% 1-Year Est. Return
MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Nan Fung Group Holdings's Q3 2023 Portfolio in Review

As of Q3 2023, Nan Fung Group Holdings held 44 positions worth $123M, down 21% from $156M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Nan Fung Group Holdings withdrew a net $6.88M in Q3 2023, closing 5 positions and reducing 3 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $4.41M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology.

Against the trend, Nan Fung Group Holdings opened a new position in Alpine Immune Sciences Inc worth $2.09M.

  • Nan Fung Group Holdings's largest Q3 2023 buy was Alpine Immune Sciences Inc: 182,280 shares worth $2.09M.
  • Nan Fung Group Holdings added most to Geron in Q3 2023, an estimated $992K increase.
  • Nan Fung Group Holdings's biggest Q3 2023 reduction was Oculis Holding, cutting an estimated $557K.
  • Nan Fung Group Holdings fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $4.41M.
  • Nan Fung Group Holdings's ten largest holdings make up 82% of its $123M portfolio in Q3 2023.
  • Nan Fung Group Holdings opened 1 new position and closed 5 in Q3 2023.
  • Nan Fung Group Holdings's portfolio value fell 21% quarter-over-quarter to $123M.

Based on Nan Fung Group Holdings's 13F filing for Q3 2023, filed 13 Nov 2023.